John Bishop, Ph.D., serves as Chief Technical and Quality Officer at Ardelyx Inc., a biopharmaceutical company focused on developing first-in-class medicines to improve outcomes for patients with kidney disease, gastrointestinal diseases, and metabolic conditions. With more than 25 years of experience in the pharmaceutical and biotechnology industries, Dr. Bishop brings deep expertise in technical operations, quality assurance, and regulatory compliance. He earned his Ph.D. in Chemical Engineering from the University of California, Berkeley, and has held progressive leadership roles at companies including Relypsa (acquired by Galenica), where he contributed to the successful commercialization of the hyperkalemia therapy Veltassa. Throughout his career, Dr. Bishop has spearheaded the scale-up of complex manufacturing processes, achieving multiple FDA approvals and ensuring seamless transitions from clinical development to commercial production. Notable achievements include implementing advanced quality management systems that reduced manufacturing deviations by over 50% at previous organizations and leading cross-functional teams to navigate stringent regulatory inspections from the FDA and EMA. His strategic approach to process validation and supply chain optimization has been instrumental in accelerating product launches while maintaining the highest standards of product quality and patient safety. At Ardelyx, Dr. Bishop oversees all technical operations, quality systems, and manufacturing activities, playing a pivotal role in the company's pipeline advancement, including the blockbuster IBSRELA for irritable bowel syndrome with constipation (IBS-C) and Ibsrela for chronic idiopathic constipation (CIC). Under his leadership, Ardelyx has strengthened its operational infrastructure to support global expansion and sustained growth, positioning the company for continued innovation in cardiorenal and GI therapeutics.